Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) has reported encouraging one-month safety and vision performance results for the first Group 1 patients who received the Ocumetics Accommodating Intraocular Lens. The company described the outcomes as a historic milestone for both Ocumetics and ophthalmology.
President and CEO Dean Burns stated, 'The safety profile and visual outcomes we're seeing at this early stage are what we hoped for, and we are excited to continue building momentum as the clinical trial progresses.' The early results highlight the transformative potential of the lens and provide a foundation for continued clinical progress.
Dr. Doyle Stulting, Chief Medical Officer, noted that after one month, initial patients are already achieving functional distance vision of 20/40 or better without glasses and showing encouraging signs of near vision performance with no complications. 'These results give us confidence the outcomes will continue to improve in the months ahead,' he added.
Dr. Garth Webb, Chief Scientist and Founder, commented, 'Seeing these early clinical results come to life is incredibly inspiring, and I believe we are only beginning to see the true potential of the Ocumetics Accommodating Intraocular Lens.' The company emphasizes that continued improvement is expected as patients adapt and the clinical program advances.
The first-in-human clinical protocol is designed to enroll three patient groups, with the one-month evaluation focusing on safety, surgical technique, and distance vision correction. The lens is designed to fit within the natural lens compartment of the eye and allow natural muscle activity to shift focus from distance to near, potentially eliminating the need for corrective lenses.
Ocumetics is a Canadian research and product development company dedicated to developing advanced vision correction solutions. The company is currently in the first-in-human early feasibility study phase for its intraocular lens technology. For more information, visit the original release at https://www.newmediawire.com.
